Daiwa Securities Group Inc. increased its position in Hologic, Inc. (NASDAQ:HOLX) by 1,298.5% during the second quarter, Holdings Channel reports. The institutional investor owned 95,799 shares of the medical equipment provider’s stock after buying an additional 88,949 shares during the period. Daiwa Securities Group Inc.’s holdings in Hologic were worth $4,348,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Lebenthal Lisanti Capital Growth LLC acquired a new position in shares of Hologic during the second quarter valued at about $891,000. CAPROCK Group Inc. acquired a new position in shares of Hologic during the second quarter valued at about $214,000. CIBC Asset Management Inc boosted its position in shares of Hologic by 3.2% in the second quarter. CIBC Asset Management Inc now owns 37,285 shares of the medical equipment provider’s stock valued at $1,692,000 after buying an additional 1,149 shares during the period. Honkamp Krueger Financial Services Inc. boosted its position in shares of Hologic by 1.0% in the second quarter. Honkamp Krueger Financial Services Inc. now owns 25,578 shares of the medical equipment provider’s stock valued at $1,161,000 after buying an additional 254 shares during the period. Finally, Great West Life Assurance Co. Can boosted its position in shares of Hologic by 1.2% in the second quarter. Great West Life Assurance Co. Can now owns 209,607 shares of the medical equipment provider’s stock valued at $9,499,000 after buying an additional 2,483 shares during the period. Institutional investors and hedge funds own 94.46% of the company’s stock.

Hologic, Inc. (NASDAQ HOLX) opened at 39.03 on Tuesday. The company’s 50-day moving average is $45.06 and its 200 day moving average is $42.98. The company has a market capitalization of $10.95 billion, a price-to-earnings ratio of 14.54 and a beta of 0.90. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same period in the previous year, the firm earned $0.51 earnings per share. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, analysts forecast that Hologic, Inc. will post $2.01 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Shares Bought by Daiwa Securities Group Inc.” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/hologic-inc-holx-shares-bought-by-daiwa-securities-group-inc.html.

Several equities analysts have issued reports on HOLX shares. Canaccord Genuity restated a “buy” rating and issued a $53.00 price target on shares of Hologic in a research report on Tuesday, May 9th. Stifel Nicolaus upped their price target on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, May 11th. BTIG Research restated a “buy” rating and issued a $47.00 price target on shares of Hologic in a research report on Sunday, May 14th. Zacks Investment Research cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Finally, Jefferies Group LLC set a $49.00 price target on shares of Hologic and gave the company a “buy” rating in a research report on Sunday, May 28th. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $48.64.

In other Hologic news, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 9,076 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $42.80, for a total transaction of $388,452.80. Following the transaction, the director now directly owns 43,165 shares in the company, valued at $1,847,462. The disclosure for this sale can be found here. Over the last three months, insiders have sold 70,464 shares of company stock worth $3,078,921. Insiders own 0.79% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.